Cabaletta Bio, Inc. is a US-based pharmaceutical company with an ESG score of 27.8, placing it at a medium risk level. Specializing in the development of engineered T cell therapies, the company focuses on treating B cell-mediated autoimmune diseases. Their innovative proprietary technology, utilizing Chimeric AutoAntibody Receptor (CAART) cells, targets specific disease-causing B cells while preserving normal B cells. With a focus on sustainability and governance, Cabaletta Bio's CABA platform offers promising treatment options for a wide range of autoimmune diseases.